Literature DB >> 27168566

Is Hydroxyethyl Starch Safe in Penetrating Trauma Patients?

Casey J Allen1, Xiomara D Ruiz1, Jonathan P Meizoso1, Juliet J Ray1, Alan S Livingstone1, Carl I Schulman1, Nicholas Namias1, Kenneth G Proctor1.   

Abstract

OBJECTIVES: For logistic reasons, a bolus of 6% hydroxyethyl starch (HES 450/0.7 in lactated electrolyte injection) is recommended for battlefield resuscitation even though it has risks of mortality and acute kidney injury (AKI) in certain patient populations. The purpose of this study was to test the hypothesis that victims of penetrating trauma have no increased risks of AKI and/or death when receiving a single bolus of HES during initial fluid resuscitation.
METHODS: 816 consecutive admissions with penetrating trauma were reviewed. Patients who died within 24 hours were excluded. Propensity scores and a 1:1 fixed ratio nearest neighbor matching were used to compare those who received HES to those who did not. Data were expressed as mean ± SD and significance was assessed at p < 0.05.
RESULTS: The cohort was 88% male, age 35 ± 14 years, injury severity score of 10 ± 10, with a 3.8% rate of AKI, and 3.2% rate of mortality. HES was administered to 121 (14.8%) patients. In HES and no HES propensity matched groups, the rate of AKI was 3.8% vs. 4.8% (p = 0.749) and the 90-day mortality rate was 3.8% vs. 4.8% (p = 0.749).
CONCLUSION: An increased risk of mortality or AKI was not observed in penetrating trauma patients who were resuscitated with low volume HES. Reprint &
Copyright © 2016 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27168566     DOI: 10.7205/MILMED-D-15-00132

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  1 in total

1.  Synthetic colloid resuscitation in severely injured patients: analysis of a nationwide trauma registry (TraumaRegister DGU).

Authors:  Peter Hilbert-Carius; Daniel Schwarzkopf; Konrad Reinhart; Christiane S Hartog; Rolf Lefering; Michael Bernhard; Manuel F Struck
Journal:  Sci Rep       Date:  2018-08-01       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.